U.S. health officials move toward wider access to controversial peptide injections

The Trump administration is advancing a policy that could make certain unapproved peptide injections easier to compound, even as FDA materials continue to flag safety and quality concerns.
U.S. and Zambia finalize a health funding deal after dropping data terms

The agreement sets a five-year health financing package while removing disputed patient-data and specimen-sharing language that had delayed the deal.
FDA maps out next wave of AI oversight for medical devices

The FDA’s new fiscal 2027 guidance list shows that artificial intelligence will remain a major focus, with planned documents on AI-enabled device software, generative AI, and related evidence standards.
Americans Worry AI Is Moving Faster Than Safeguards in Health Care

A new AP-NORC poll finds broad concern that artificial intelligence is advancing too quickly, a worry that carries special weight as AI tools expand in medicine and public health.
Canadian Mail-Order Prescriptions Face a New Hurdle

A U.S. customs change could make it harder and more expensive for some Americans to receive prescription medicines from Canada, raising fresh concerns about drug affordability and continuity of care.
When insurance delays hit COPD care, the stakes can be high

A reported death tied to delayed COPD medication highlights how coverage barriers can disrupt treatment for adults with chronic lung disease—especially after age 45.
Kennedy’s AI Push Raises New Questions for Patients 45+

RFK Jr.’s embrace of artificial intelligence is drawing support and skepticism. Here’s what adults 45+ should know about the promise, limits, and risks of AI in care.